Ilika PLC (AIM:IKA, OTCQX:ILIKF, FRA:I8A), the British battery technology company, has received its first commercial order from Cirtec Medical for components used in its miniature solid-state batteries — a deal that marks the company’s move from R&D into revenue-generating production.
The order, announced today, covers the supply of electrodes, conductive elements at the heart of Ilika’s Stereax batteries, and follows more than two years of development work with Cirtec, a US-based manufacturer of implantable medical devices. Ilika delivered initial prototypes in December.
Cirtec will use the electrodes to ramp up manufacturing of its Stereax M300 batteries, which are designed for powering a new generation of medical implants, including neurostimulators, orthopaedic and orthodontic devices, and implanted sensors.
Ilika said the order signals “the commercial transition of this strategic partnership”.
The companies first formalised their relationship in 2023, with Ilika retaining some production capability at its UK facility to support Cirtec, which manufactures the batteries at its site in Massachusetts. Ilika will now act as a supplier of key materials for scaled-up production.
The Stereax M300 battery is currently being tested by 21 customers in the medical technology sector, according to the company.
Graeme Purdy, Ilika’s chief executive, said: “The receipt of this first commercial electrode order validates the strong market momentum building behind our Stereax technology and demonstrates the successful execution of our production strategy.”
Shawn Martin, vice-president at Cirtec Medical, added: “This marks an important transition from the earlier stages of technology transfer to commercial production coordinated from our facility here in the USA.”
The two companies are expected to showcase the technology at industry events in the US over the coming weeks, including the North America Neuromodulation Society’s annual meeting in Las Vegas and the MD&M West medical device conference in California.